Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Localised prostate cancer, high and very high risk
Data

Cancers·Localised prostate cancer, high and very high risk

DataLocalised prostate cancer, high and very high risk

Back to the Localised prostate cancer, high and very high risk hub →49 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

49

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
Non-metastatic castration-resistant prostate cancer
Shares PSA (prostate-specific antigen), Biochemical recurrence of prostate cancer, Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors and the tag subtype-page.
Cancer
Neuroendocrine and small-cell prostate cancer
Shares Metastatic hormone-sensitive prostate cancer, Androgen deprivation & AR pathway inhibitors, PSMA PET, Prostate cancer and the tag subtype-page.
Cancer
Early cervical cancer and fertility-sparing surgery
Shares Brachytherapy, Robotic & minimally invasive surgery, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
Locally advanced cervical cancer
Shares Brachytherapy, Robotic & minimally invasive surgery, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
Uterine carcinosarcoma
Shares Brachytherapy, Robotic & minimally invasive surgery, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
Endometrial cancer with no specific molecular profile
Shares Brachytherapy, Robotic & minimally invasive surgery, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
p53-abnormal endometrial cancer, including uterine serous carcinoma
Shares Brachytherapy, Robotic & minimally invasive surgery, IMRT / IGRT (modern external beam) and the tag subtype-page.
Cancer
POLE-ultramutated endometrial cancer
Shares Brachytherapy, IMRT / IGRT (modern external beam) and the tag subtype-page.

technologies

10

Active surveillance Androgen deprivation & AR pathway inhibitors Brachytherapy Digital pathology & AI Endocrine therapy (SERMs, AIs, SERDs)IMRT / IGRT (modern external beam)Pathology & radiology foundation models PSMA PET RNA sequencing & expression profiling Robotic & minimally invasive surgery

targets

1

Androgen receptor

drugs

6

ApprovedSmall-molecule CYP17A1 inhibitor

Abiraterone acetate · Zytiga (generic)

ApprovedAI digital pathology prognostic/predictive test

ArteraAI Prostate

EstablishedGene-expression genomic classifier

Decipher Prostate

ApprovedGnRH antagonist depot

Degarelix · Firmagon

ApprovedGnRH agonist depot

Leuprolide (leuprorelin) and GnRH agonists · Lupron / Eligard / Camcevi

ApprovedOral GnRH antagonist

Relugolix · Orgovyx

companies

10

AbbVie (incl. ImmunoGen, Capstan)Artera Ferring Pharmaceuticals Foresee Pharmaceuticals Johnson & Johnson MRC Clinical Trials Unit at UCL Oakwood Laboratories Sumitomo Pharma (Myovant)Takeda Veracyte (Decipher)

terms

2

Biochemical recurrence (BCR)PSA (prostate-specific antigen)

trials

13

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have Hi An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer HYPO-RT-PC Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy proPSMA PSMA-PreRP STAMPEDE

people

1

Gerhardt Attard

key papers

6

D'Amico risk groups: biochemical outcome after radical prostatectomy, external beam radiotherapy or brachytherapy Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial EORTC 22863: improved survival with radiotherapy plus goserelin in locally advanced prostate cancer proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer STAMPEDE: abiraterone with or without enzalutamide added to androgen deprivation for high-risk non-metastatic prostate cancer STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-17. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link cancer subtypes to their siblings and name parents i… · diff · file

Wikipedia

Prostate cancer staging

Sources & links

Wikipedia
NCCN Guidelines: Prostate Cancer

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Localised prostate cancer, high and very high risk

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/prostate-high-risk/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id prostate-high-risk.

WebMCP tools registered on this page: onco_search, onco_get_entity.